Alnylam Pharmaceuticals, Inc.
ALNYNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $31.43B
- P/E (TTM)
- 38.90
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $197.81$490.05
- Volume (live)
- -
- Avg. volume (3M)
- 1.33M
Alnylam Pharmaceuticals (ALNY) Stock Price & Financial Analysis
Alnylam Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $223.76 - $229.82 |
|---|---|
| 52-Week High | $490.05 |
| 52-Week Low | $197.81 |
| Open | $224.92 |
| Volume (last close) | 2.21M |
| Average Volume (3M) | 1.33M |
| Revenue (TTM) | 4.80B |
|---|---|
| Net Income (TTM) | 807.99M |
| Free Cash Flow (TTM) | 793.95M |
| EPS (TTM) | $5.87 |
| Profit Margin | 16.82% |
| Operating Margin | 20.81% |
| Return on Equity (ROE) | 59.67% |
| Debt to Equity | 0.78 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 31.43B |
|---|---|
| Shares Outstanding | 138.28M |
| P/E Ratio (TTM) | 38.90 |
| Price to Sales (P/S) | 6.54 |
| Price to Book (P/B) | 23.21 |
| EV/EBITDA | 24.35 |
| 50-Day MA | $238.97 |
|---|---|
| 200-Day MA | $292.63 |
| 1-Year Change | −51.02% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Alnylam Pharmaceuticals at a Glance
As of the Oct 22, 2026 close, Alnylam Pharmaceuticals (ALNY) has a market capitalization of $31.43B. The stock trades at 38.9× trailing earnings and 6.5× sales. Over the trailing twelve months it earned $807.99M on revenue of $4.80B (a 16.8% profit margin) and generated $793.95M of free cash flow. Revenue grew 95.1% year over year.
As of its latest reported balance sheet, it holds $1.71B in cash and securities against $1.06B of debt, a net cash position of $651.40M.
Alnylam Pharmaceuticals does not currently pay a dividend.
The share price is down 51.0% over the past year. At $227.28 (the Oct 22, 2026 close) it sits near the bottom of its 52-week range of $197.81 to $490.05, below its 200-day moving average of $292.63.
Based on 25 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $363.39, 59.9% above the Oct 22, 2026 close.
Frequently Asked Questions About Alnylam Pharmaceuticals
What is the current stock price for ALNY?
As of the Oct 22, 2026 close, ALNY stock trades at $227.28. The 52-week range is $197.81–$490.05, with a day range of $223.76–$229.82.
What is the P/E ratio for ALNY?
As of the Oct 22, 2026 close, Alnylam Pharmaceuticals's trailing twelve-month (TTM) P/E ratio is 38.9, meaning investors pay $38.9 for every $1 of annual earnings. Alnylam Pharmaceuticals operates in the Healthcare sector.
Does ALNY pay dividends?
Alnylam Pharmaceuticals does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for ALNY?
Based on ratings from 25 professional analysts over the last 90 days, the consensus for ALNY is Buy. The average 12-month price target is $363.39, a 59.9% upside from the Oct 22, 2026 close of $227.28.
What is the market cap of ALNY?
As of the Oct 22, 2026 close, Alnylam Pharmaceuticals's market capitalization is $31.43B, classifying it as a large-cap company. Alnylam Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.